GJB2 and deafness: Our results revealed that for children who received CIs before the age of 3.5 years, patients with mutations in common deafness genes, including GJB2 and SLC26A4, demonstrated significantly better long-term auditory performance and speech intelligibility at post-implant year 3 and 5 than those without mutations.